SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (412)5/21/2003 6:27:14 PM
From: Icebrg   of 631
 
Isotechnika - ISA.TO

I have joined the Isotechnika camp. This is indeed very interesting. The company had its annual meeting today with a webcasted presentation of their technology and development status. Some key points:

- ISA 247 is a cyclosporin analogue with less toxicity and higher potency than the original.

- The drug is in clinical development for renal transplantation and psoriasis at present (there were some stunning photos of psoriasis patients before and after).

- ISA 247 is an orally available small-molecule drug.

- The drug is partnered with Roche, who has agreed to pay milestones of up to 210 mUSD to Isotechnika during the drug's development (Roche is as usual very generous. They want their partners to thrive).

- The company appears as somewhat of a Sepracor look-alike. They take other company's drugs and improve them. They have even "snatched" one of Sepracor's own isomers.

- This looks to my rather untrained eye as a penalty kick (to use a socker term after today's UEFA Cup final). If they are able to develop this drug without any significant side-effects appearing (like QTc-prolongations etc.), it may well become the standard of care for both psoriasis and in transplantation settings. The normal cyclosporin side-effects, which are bad, appear to already have been accounted for.

The company is well worth to visit at

isotechnika.com

Erik
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News